SIRPA and neoplasm: Cho et al. [48] compared the tumor immunotherapy effects of SIRPα-rich exosomes and ferritin and demonstrated that intratumoral injection of SIRPα-rich exosomes more effectively inhibited tumor growth, indicating that the blocking ability of the exosome-mediated CD47/SIRPα pathway was significantly stronger than that of ferritin at the same dose.